Nvest Financial LLC Invests $693,000 in Geron Co. (NASDAQ:GERN)

Nvest Financial LLC purchased a new position in shares of Geron Co. (NASDAQ:GERN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 195,741 shares of the biopharmaceutical company's stock, valued at approximately $693,000.

Several other institutional investors have also recently made changes to their positions in the company. Readystate Asset Management LP purchased a new stake in Geron during the third quarter worth $58,000. Rovin Capital UT ADV lifted its stake in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after purchasing an additional 3,660 shares during the last quarter. Monterey Private Wealth Inc. bought a new stake in Geron during the fourth quarter valued at about $63,000. Empowered Funds LLC purchased a new position in Geron in the third quarter valued at about $67,000. Finally, Inspire Advisors LLC bought a new position in Geron in the third quarter worth about $68,000. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Price Performance

Shares of Geron stock traded down $0.01 during mid-day trading on Friday, reaching $2.87. 10,687,533 shares of the stock traded hands, compared to its average volume of 9,232,478. The stock has a market capitalization of $1.73 billion, a PE ratio of -8.97 and a beta of 0.55. The business has a 50-day moving average of $3.49 and a 200 day moving average of $4.06. Geron Co. has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The firm had revenue of $28.27 million during the quarter, compared to analysts' expectations of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business's revenue for the quarter was up 17138.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.08) earnings per share. On average, analysts predict that Geron Co. will post -0.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GERN. Barclays raised Geron to a "strong-buy" rating in a research report on Friday, November 29th. HC Wainwright reissued a "buy" rating and issued a $9.00 price target on shares of Geron in a report on Tuesday, December 10th. Needham & Company LLC upped their price objective on shares of Geron from $6.00 to $7.00 and gave the company a "buy" rating in a report on Monday, January 13th. Finally, Scotiabank assumed coverage on shares of Geron in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $6.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.25.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.